Hepato Papers “Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150”
25 de julho de 2023
![destaque-papers-fabio.png](https://sbhepatologia.org.br/wp-content/uploads/2023/07/destaque-papers-fabio.png)
Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150 é o novo artigo comentado do Hepato Papers, comentado pelo hepatologista, Dr. Fábio Marinho.